IRVINE, CA--(Marketwired - Nov 30, 2016) - Central Admixture Pharmacy Services, Inc. (CAPS®) will present its new quality assurance program requiring 100 percent release testing of all of its compounded drugs and other products at this year's American Society of Health-System Pharmacists (ASHP) 51st Midyear Clinical Meeting.
From Dec. 5-7 in the Mandalay Bay Convention Center in Las Vegas, CAPS representatives will be at booth #2413 to discuss the company's Test, Hold and Release (THR(SM)) program, which is designed to ensure that every compounded drug batch from CAPS' 503B outsourcing facilities meets the new standards for cGMP release testing for sterility, potency, and endotoxin testing prior to release and shipment. CAPS also offers a Certificate of Release for each batch to give customers peace of mind.
"Our existing high quality standards are strengthened with THR implementation, which requires 100 percent release testing on all of our products," said Mike Koch, Senior Vice President, CAPS Professional Services. "When it comes to patient safety and the reputation of our customers, we believe that THR for every batch is the only way to assure the level of quality that's demanded by pharmacists and clinicians to enhance patient outcomes."
CAPS was among the first outsourcing admixture pharmacies in the nation to adopt release testing.
"CAPS is at the forefront of helping hospitals and surgery centers navigate through the new compounding regulatory environment," Koch said. "Our goal is to provide our customers with programs such as THR and consultative services to help them focus on improving patient care."
A market leader in customized Parenteral Nutrition (PN) delivery and provider of quality sterile compounding services for the past 25 years, CAPS also will feature CAPS Consulting(SM), a new service designed to help hospital pharmacists and pharmacies remain compliant in light of new regulations as a result of the Drug Quality & Security Act. CAPS Consulting offers comprehensive evaluations of pharmacies, assesses compliance readiness, and provides recommendations and training.
CAPS is the nation's largest network of outsourcing admixture pharmacies. A pioneer in the outsourcing of CSPs, CAPS was founded in 1991, and delivers high-quality, same-day, admixture services and solutions to hospitals and outpatient facilities across the nation. CAPS has two 503B Outsourcing Facilities that are registered with the FDA to provide anticipatory compounding services. CAPS also has 22 state licensed 503A regional pharmacies that dispense labeled, patient-specific prescriptions including PN and chemotherapy. To learn more, visit www.capspharmacy.com.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.